English
Diviser par deux le prix des prothèses bioniques et des organes artificiels
Hélice est une ingénierie financière innovante basée sur la blockchain qui vise à diviser par deux le prix des prothèses bioniques et des organes artificiels.
Parmi ces technologies, on retrouve les implants rétiniens, les bras prothétiques, les neuroprothèses, les cœurs artificiels, les exosquelettes, etc.
Nous sommes frustrés par les prix exorbitants de ces technologies (≈100 000 $) et la lenteur du développement dans ces domaines.
La nature hautement personnalisée de ces dispositifs rend la production à grande échelle complexe, ce qui entraîne des prix élevés.
De plus, les biotechs peinent à faire progresser l’innovation, car il peut leur falloir jusqu’à 10 ans pour générer des revenus, ce qui se traduit par des investissements limités dans ce secteur.
C’est ici que l’ingénierie d’Hélice entre en jeu. Tout d’abord, en brisant le cercle vicieux grâce à la division par deux des prix, et ensuite, en générant un afflux de capitaux pour accélérer le développement de ces technologies au sein de notre futur laboratoire.
Un premier patient en 2021
Bien que le token ne soit pas encore en circulation, Dylan a eu l’opportunité d’être le premier patient à bénéficier du programme Hélice. Il cherchait des fonds pour acquérir la prothèse de genou la plus avancée disponible, le Genium x3, au coût de 107 000 €. Hélice est intervenu pour l’aider en offrant quelques tokens à des personnes prêtes à contribuer financièrement. Ces individus auront accès aux tokens lors du lancement officiel.
Tokenomics
Max Supply of 1 Unit
$HELICE est très rare et déflationniste en raison de sa quantité maximale de 1 unité. Nous croyons que la valeur élevée du token (qui sera égale à sa capitalisation boursière) sera un symbole de la qualité du projet et renforcera la réputation de notre marque axée sur les biotechnologies les plus avancées. En effet, celle-ci serait dévaluée si le token avait une valeur de $0,00…. Nous pensons qu’une valeur perçue élevée attirera davantage d’investisseurs à long terme ainsi que d’excellents partenaires pour propulser notre croissance.
Taxes and passive income.
Pour financer les prothèses, Hélice appliquera une taxe de 2,9 % sur son token (achat/vente). De plus, une taxe de 1,3 % (achat/vente) sera redistribuée sous forme de revenu passif aux investisseurs qui conservent leurs tokens
Buyback & Burn
La quantité de $HELICE diminuera encore avec le temps, grâce au rachat et à la destruction initiés à chaque vente de prothèse.
Tokenomics
Roadmap
2021
Premier patient : Dylan
Partenariats supplémentaires
2023
Premier Halving et premier buyback-burn
2023
Plus de 100 patients équipés avec les prothèses les plus avancées
2025/2026
Création du modèle Hélice
Présentation à la communauté
2023
Token disponible
2023
Premier milestone (non-divulgé)
2023/2024
Création d’un laboratoire de R&D avec nos partenaires
Partners
Roadmap
2021
Création du modèle Hélice Model
Premier patient : Dylan
Présentation à la communauté
2023
Partenariats supplémentaires
2023
Token disponible
2023
Premier Halving et premier buyback-burn.
2023/2024
Plus de 100 patients équipés avec les prothèses les plus avancées
2023/2024
Premier milestone (non-divulgé)
2025/2026
Création d’un laboratoire de R&D avec nos partenaires
Advisors & Team (non-exhaustif)
Bernard Verrier | Ph.D in Biology
Director of the “Tissue Biology and Therapeutic Engineering” department at the IBCP (CNRS & University of Lyon).
Born in France in 1957 and trained as a chemist, before getting a phD in molecular virology in 1985 and post-doctorated for three years at the EMBL, Germany, in retroviral oncology. Then, he moved to Lyon (France) to study human retrovirology, designing HIV vaccine candidates, either therapeutic, using tat,rev or nef regulatory proteins or prophylactic, with gp140 constructs, through a permanent position at CNRS. Director of research from CNRS since 2004, he was head of a joint unit between CNRS and bioMerieux, dedicated to HIV and HCV therapeutic vaccines.
Anton Sindali | Doctor of Medecine
Doctor of Medicine thesis (hepatic surgery).
Diplomas of 3rd cycles of university studies in Marseille (Aix- Marseille II): Qualified in General Surgery, University Diploma in Anaesthesia – Intensive Care, University Diploma in Pathological Anatomy, University Diploma in Abdominal Ultrasound, University Diploma in Digestive Endoscopy.
Diplomas of 3rd cycles of university studies in Paris (Paris XI): University Diploma in Laparoscopic Abdominal Surgery (Paris School of Surgery, Kremlin-Bicètre), University Diploma in Clinical Oncology Villejuif (IGR).
Denis Chriqui | Ph.D in Economics
Economist and former professional trader. After a Ph.D in economics from the University of Montpellier and training at the Wharton School, Denis was for more than 16 years a business buyer, professor of economics, specialist and researcher in behavioral finance, trainer in technical analysis and director of an import-export company. He worked as a professional trader in New York at Herzog Heine Geduld (Merrill Lynch) and E Trade for more than 6 years as an arbitrageur-strategist on derivatives, then in portfolio management and front office manager. Since 2004, Denis has been devoting himself to his vocation for teaching and proprietary trading.
Thierry Monmasson | Ph.D In Pharmaceutical Sciences
1993: Pharmacist Diploma: six-year university degree in industrial pharmacy with honors at the University of Pharmacy of Marseille. 1998: Master degree in Sciences, speciality Biochemistry and genetics at the University of medecine of Marseille. 1999: Diplôme d’études approfondies: one-year degree before postgraduate studies in cellular and molecular biology at the University of medecine of Marseille.
RESEARCH : Study of chaperone proteins and thyroid hormonegenesis, contribution to the study of the action of the disulfide isomerase protein in the thyroglobulin metabolism.
Olivier Rousselle | Ph.D In Quantum Physics
Passionate by science and by the universe, Olivier has obtained a PhD in quantum physics at Sorbonne Université in 2022. He has dealt with different research topics until now: particle physics and software development at CERN; foundations of quantum physics at ENS; modeling and statistics at CNRS; biology and environmental studies at AgroParisTech. Moreover, he is passionate about the crypto / blockchain ecosystem, and he is currently involved in the development of efficient crypto algorithmic bots.
Curriculum : PhD in Physics at Sorbonne Université (2019-2022).
Master in Theoretical Physics at Aix-Marseille Université (2018-2019).
Engineer School AgroParisTech (2013-2017).
Florian Ravaz | Ph.D in Law
2007-2010 : Law degree (University of Toulon)
2010-2011 : Master of Law, Mention public law and private law (University of Toulon)
2011-2012 : Master of Notarial Law (University of Toulon).
2012-2016 : PhD in public law on “Taxation of non -resident foreigners in France”, very honorable mention (University of Toulon).
Jaime Lourenço | Ph.D in Economics
Samuel G. Ongala-Eedoumou I MSc In Physics
Master’s Degree – Magnetic Fusion Confinement Université Pierre et Marie Curie (Paris VI) 2012 – 2015
Diploma in Basic Physics International Center for Theoretical Physics Trieste, Italy 2011 – 2012
Maitrise de Physique Université Marien Ngouabi Congo 2009 – 2010
Licence de Physique Université Marien Ngouabi Congo 2008 – 2009
Adrien Marchand | MSc In International Finance
ESM IAE Metz Master 2, International Finance · (2017 – 2018)
Saint Petersburg State University of Economics. Master 1 International Management · (2016 – 2017)
Université d’Angers – Bachelor of Science in Economics and International management · (2015 – 2016).
Lucas Ewig I Master in Management & MSc Corporate Financial Management
Master in Management & MSc Corporate Financial Management
SKEMA Business School – 2022
-Blockchain & Cryptocurrencies
-Corporate Finance & Financial Markets
Bachelor’s degree in Economics and Management – Faculty of Economics and Management of Strasbourg – 2019
(top 3% of promotion)
Jérôme Sohier | Ph.D in Biomedical engineering
Researcher at the « Tissue Biology and Therapeutic Engineering » department at the IBCP (CNRS & University of Lyon).
Born in France in 1976 and trained as a polymer chemist, Dr. Sohier was a junior researcher in the first European tissue engineering company (IsoTis) prior to obtaining a Ph.D. in biomedical engineering from the university of Twente (Netherlands) in 2006. He then continued his studies and developments of regenerative medicine strategies in post-doctoral appointments in Nantes (Lab. of osteoarticular and dental engineering INSERM) and London (Imperial College, National Heart and Lung Institute). He has a strong interest in translating his research to patients needs and had the opportunity of participating in the creation of a startup company dedicated to bone repair, based on an innovative technology that he invented. Since 2012, he is a permanent researcher in Lyon, where he continues to develop translatable approaches to repair and regenerate various tissues, for which there are no therapeutic alternatives.
Mickaël LEB | MSc Financial Markets and Investments & Master en Management
Passionate about finance, economics and geopolitics, Mickael graduated with a double degree in Finance and Management.
Since 2018, he developed his expertise in the investment management and advisory industry through his international experiences in Asset Management and Wealth Management among global industry top players.
Mickael is currently the Head of Sales in a world leading Private Bank.
His interest in the blockchain ecosystem as well as his exposure to cryptocurrency investments led him to become an Advisor at Hélice.
Zackary E. | Marketing Advisor
William Kabaz I Master in International Management
Seasoned expert in digital asset management, holds a Bachelor’s degree in Economics and Finance from ASSAS Paris-II and a Master’s from NEOMA Business School. He has over three years of hands-on experience in managing private cryptocurrency funds and day trading. His familiarity with DeFi and Web 3 protocols, coupled with his strong background in economics and finance, has been instrumental in his strategic approach to investment.
Héloïse Ravaz | Founder and CEO
And that’s not all !
Hélice works closely with over a dozen other experts, including scientists, researchers, economists, traders, physicists, engineers, doctors, lawyers, and more….
Bernard Verrier | Ph.D In Biology
Anton Sindali | Surgeon
Denis Chriqui | Ph.D In Economics
Thierry Monmasson | Ph.D In Pharmaceutical Sciences
Olivier Rousselle | Ph.D In Quantum Physics
Florian Ravaz | Ph.D In Law
Jaime Lourenço | Ph.D In Economics
Héloïse Ravaz | Founder & CEO Of Hélice
Samuel G. Ongala-Eedoumou I MSc In Physics
Adrien Marchand | MSc In International Finance
Lucas Ewig I Master in management / MSc in corporate financial management
In the Press
NFT whitelist (limited offer) :
